Clinical trials: Tauopathies
Alzheimer Disease and Related Dementias
Home-based tDCS for Apathy in Alzheimer's Disease
The purpose of this study is to assess feasibility, acceptability, and safety of providing tDCS to Alzheimer's disease and related dementias (ADRD) patients with apathy and to assess the efficacy of tDCS for ADRD-related…
- Trial name
- NCT04855643
- Testing
- home-based active tDCS
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The University of Texas Health Science Center, Houston
Alzheimer's Disease
Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects
A Randomized, Double-blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Alzheimer's Disease
- Trial name
- NCT03817684
- Testing
- BPN14770
- Where
- 41 sites in United States
- Volunteers
- 255 people
- Sponsor
- Tetra Discovery Partners
Mild Cognitive Impairment
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
This study is intended to examine the impact of receiving a genetic risk assessment for Alzheimer's disease (AD) among individuals with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01434667
- Testing
- APOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
- Where
- 3 sites in United States
- Volunteers
- 146 people
- Sponsor
- Brigham and Women's Hospital
Diabetes, Senile Dementia, Alzheimer Type
A Study of Mobile Medical Supportive Care Program for Family Caregivers With Dementia Combined With Diabetes
The purpose of this project is to evaluate the effectiveness of the clinical application of a mHealth supportive care program for family caregivers with dementia combined with diabetes based on the supportive care framework.
- Trial name
- NCT06785857
- Testing
- mHealth Supportive Care Program, Offline supportive care
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yuanjiao Yan
Alzheimer's Disease, Vascular Dementia
Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and other cognitive functions.
- Conditions
- Alzheimer's Disease, Vascular Dementia, Dementia, Memory Impairment
- Trial name
- NCT01965756
- Testing
- Metformin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Alzheimer Disease, Mild Cognitive Impairment
Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges
The objectives of this study are to demonstrate the feasibility of implementing a deprescribing nudge intervention using pragmatic methods, confirm that outcomes can be feasibly measured and evaluated at scale in a subsequent…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- NCT06347172
- Testing
- Nudge Intervention
- Where
- United States
- Volunteers
- 262 people
- Sponsor
- Brigham and Women's Hospital
Alzheimer Disease
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested
- Trial name
- NCT03703856
- Testing
- Memantine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of California, San Diego
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
The proposed study is designed to evaluate the performance of the ALTOIDA™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Disorders, Cognitive Impairment
- Trial name
- AltoidaML (NCT02843529)
- Testing
- Altoida: neuropsychological, MRI, EEG and CSF biomarkers
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Altoida
Alzheimer's Disease
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD 2 (NCT03114657)
- Testing
- Crenezumab
- Where
- 211 sites in United States, Argentina and 25 more
- Volunteers
- 806 people
- Sponsor
- Hoffmann-La Roche
Depression
Prevention of Depression in Spouses of People With Cognitive Impairment
This study evaluates the effectiveness of a problem-solving training program in preventing depression in the spouses or family caregivers of persons with mild cognitive impairment or early dementia.
- Trial name
- NCT00321971
- Testing
- PST-MCI/AD Caregiving, NT-MCI/AD Caregiving
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Alzheimer's Disease
Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
This study evaluated the effect of 6 or 12 infusions of different doses of octagam (intravenous immunoglobulin [IVIG]) 10% on the reduction of amyloid beta peptide (Aβ) in cerebral spinal fluid (CSF) and on the increase of Aβ in…
- Trial name
- NCT00812565
- Testing
- octagam 10%
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Octapharma
Alzheimer's Disease
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
- Trial name
- NCT02576639
- Testing
- CNP520
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
Early stage Parkinson disease (PD) is characterized by a 'honeymoon' phase in terms of responsiveness of motor symptoms, including gait, to dopaminergic pharmacotherapy.
- Trial name
- FOG (NCT03647137)
- Testing
- Detailed motor testing, including FoG, in PD subjects
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- VA Office of Research and Development
Mild Cognitive Impairment, Alzheimer Disease
Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study
850,000 people live with dementia in the UK, with that number expected to rise to more than 1 million within the next 5 years. The most common type of dementia (55%) is Alzheimer's dementia, and vascular dementia is the second…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Vascular Dementia, Healthy Controls
- Trial name
- NCT03134963
- Testing
- Transcranial doppler ultrasonography, Blood pressure monitoring, Heart rate monitoring
- Where
- 2 sites in United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001.
- Trial name
- "MAD" (NCT05363293)
- Testing
- AL001
- Where
- 2 sites in United States, Canada
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Alzamend Neuro, Inc.
Alzheimer Disease, Dementia, Alzheimer Type
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
This is a Phase 2 study to evaluate safety and efficacy in participants with Mild Cognitive Impairment due to Alzheimer's Disease/Prodromal Alzheimer's Disease (referred to as MCI/Prodromal) and mild to moderate dementia due to…
- Trial name
- NCT02322021
- Testing
- E2609
- Where
- 21 sites in United States
- Volunteers
- 70 people
- Sponsor
- Eisai Inc.
Alzheimer Disease
A Dyadic Approach for a Remote Physical Activity Intervention in Adults With AD and Their Caregivers
The objective of this study is to compare the effectiveness of 2 intervention delivery strategies for increasing moderate physical activity (MPA), real-time group video conferencing (RGV) vs.
- Trial name
- NCT04102514
- Testing
- Real-time Group Video, Enhanced Usual Care
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- University of Kansas
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT06424236)
- Testing
- Gantenerumab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Mild to Moderate Alzheimer's Disease
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
To evaluate the efficacy of rivastigmine patch with 1-step titration on cognitive function measured as change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE) in mild to moderate Alzheimer's…
- Trial name
- ENA1stepswitch (NCT02703636)
- Testing
- Rivastigmine Patch
- Where
- 19 sites in Japan
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Imaging Inflammation in Alzheimer's Disease
This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein…
- Trial name
- NCT02831283
- Testing
- 11C-PBR28, 18F-Florbetaben, Lumbar puncture (optional)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Patrick Lao